Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning
- PMID: 24395088
- PMCID: PMC12261303
- DOI: 10.1038/nrclinonc.2013.243
Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning
Abstract
Next-generation sequencing analysis and characterization of the microenvironment ‘field-effect’ that promotes hepatocellular carcinoma (HCC) development has revealed critical players and potential targets for chemoprevention. A biomarker-based drug development strategy is needed to improve future HCC clinical trials and therapies.
Conflict of interest statement
Competing interests
A. Villanueva declares an association with the following company: Bayer Pharmaceuticals. J. M. Llovet declares an association with the following companies: Bayer Pharmaceuticals, Blueprint, BMS, Imclone-Lilly, Nanostring, Novartis. See the article online for full details of the relationships.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical